ONCOLOGY Staff

John O. Mascarenhas, MD, led a panel discussion on myelofibrosis management including the use of JAK inhibitors and transplantation.

A patient with bladder cancer recounts his diagnosis while Rohit Jain, MD, and Anand B. Shah, PharmD, BCOP, review treatment options and the toxicity associated with them.

Nelson J. Chao, MD, MBA, and his colleagues discussed the use of ruxolitinib as treatment for patients with graft-vs-host disease.

Brian I. Rini, MD, led a panel where he and his colleagues discussed the results of the CLEAR trial and its implications in renal cell carcinoma.

Experts met to debate recently presented trials in the hematologic oncology after the 2023 American Society of Clinical Oncology Annual Meeting.

Jennifer L. Garson, PA-C, gave an overview of follicular lymphoma and how she manages adverse effects in her institution.

Arvind N. Dasari, MD, and Cathy Eng, MD, gave an overview on the use of fruquintinib in colorectal cancer.

Thomas G. Martin, MD, discussed with his colleagues cytokine release syndrome after treatment with teclistamab for patients with multiple myeloma.

Robert Motzer, MD, led an expert panel to discuss the phase 3 CONTACT-03 which examined patients with renal cell carcinoma.

Ryan Jacobs, MD, and Alan Pierre Zausner Skarbnik, MD, discussed the use of acalabrutinib and zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

CancerNetwork hosted a Training Academy focused on sequencing therapies for patients with multiple myeloma who are treated with bispecific antibodies.

Experts in the field of multiple myeloma highlight key takeaways for clinicans to be aware of for infections associated with bispecific antibody multiple myeloma treatments.

Naval G. Daver, MD, reviewed current treatment options in acute myeloid leukemia, specifically the use of menin inhibitors in the space.

Saad. Z. Usmani, MD, leads a panel of experts in discussing toxicities associated with treatment for multiple myeloma.

During Morning Rounds, Petros Grivas, MD, and his treating team debate the diagnosis of a patient with urothelial carcinoma as it has an unusual presentation.

Current treatment options for patients with EGFR exon 20 non–small cell lung cancer were discussed among a panel of experts in a recent Frontline Forum.

Experts review current treatments for metastatic castration-sensitive prostate cancer, centering their discussion around a patient case.

Experts in the multiple myeloma space discuss recent developments and how to implement new practices in real-world settings.

“I’d love to see us figure out a way to optimize treatment and personalize care. Biomarkers will help us get there, but we also need to be bold in our clinical trial designs.”

Key points from a discussion of the role of bispecific antibodies in the treatment of multiple myeloma.

Key points from a discussion of the clinical data behind both BCMA- and non–BCMA-targeting bispecifics in multiple myeloma.

Experts review treatment options for acute graft-versus-host disease and discuss data from post hoc analyses of the REACH2 trial.

Experts present and discuss new findings from the CheckMate 9ER trial, evaluating nivolumab plus cabozantinib vs sunitinib in renal cell carcinoma.

A pair of experts explore the expanding treatment landscape in non–small cell lung cancer for patients with EGFR exon 20 insertion mutations.

"We’ve learned from our colleagues in breast cancer that there are opportunities to leverage this hormonal axis with combinations [including] a CDK4/6 [inhibitor]."

A panel of experts, a patient, and her caregiver discuss her renal cell carcinoma diagnosis, the prevalent treatment options, and optimal strategies for patient education.

An expert panel reviews the management of toxicities, genetic testing, and other topics in colorectal cancer.

Ashley E. Rosko, MD, recaps a recent panel discussion on treatment options for multiple myeloma, and discusses the disease space more generally.

“We’re starting to see a lot of benefits with targeted therapies [and] immunotherapies. Unfortunately, these [benefits] remain limited to a small subset of patients across GI [gastrointestinal] [malignant tumors]. One of the biggest challenges is how to expand those benefits to the majority of patients.”

Lead study author Ruben Mesa, MD, discusses findings from the MOMENTUM trial assessing the use of momelotinib in the treatment of myelofibrosis.